Risk of death associated with nesiritide in patients with acutely decompensated heart failure
about
Outcomes of patients hospitalized for acute decompensated heart failure: does nesiritide make a difference?KMUP-1 attenuates isoprenaline-induced cardiac hypertrophy in rats through NO/cGMP/PKG and ERK1/2/calcineurin A pathwaysGlobal microRNA profiles and signaling pathways in the development of cardiac hypertrophyEffects of miRNA-455 on cardiac hypertrophy induced by pressure overload.Nesiritide: a reappraisal of efficacy and safety.Overview of emerging pharmacologic agents for acute heart failure syndromes.Impact of treatment guidelines on clinical and economic outcomes of acute decompensated heart failure.Role of tolvaptan in acute decompensated heart failure.Cardiorenal syndrome in heart failure: a cardiologist's perspective.Role of natriuretic peptides in cardiovascular surgery.Medical therapy for acute decompensated heart failure: what recent clinical trials have taught us about diuretics and vasodilators.Reassessing the use of vasodilators in heart failure.Acute decompensated heart failure: evolving literature and implications for future practice.Acute Decompensated Heart Failure.Advances in the treatment of acute decompensated heart failure in the elderly.Targeting myocyte-specific enhancer factor 2D contributes to the suppression of cardiac hypertrophic growth by miR-92b-3p in mice.Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF.Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?
P2860
Q33307212-6A6A7B92-4137-4AA4-A55C-1E547D7A5C3BQ33730630-1EC2ED77-01CF-43EC-85F7-CC9AA4169560Q33822186-D9B2AEFC-3ABA-4A99-A79B-4E26D4809655Q35167896-0DF36D63-68E5-4245-9E8F-EE1D7F834C45Q36723849-A49A4028-CC05-40A1-B58B-3FEE1639EAF5Q37086309-DDCABAA9-F15F-4C68-945C-72B1F26EACEBQ37095699-DD11E81C-E1B7-4929-A091-620CC5DC37C0Q37176415-7ACEDFC5-824C-4003-B494-824F8C634760Q37217357-0158FE6F-FD7B-428B-8E5B-6D3A2D7CC8B7Q37472052-AB104327-56D0-496C-83D5-33503DC17531Q37923340-9A5E0EDC-6591-41B9-827E-4E2B7B6B5C3FQ38055507-710129A4-7E10-4A31-A754-5C0B0AA23132Q38161451-8DB4FBA7-90E0-44B6-AAE8-EA5E303DE907Q38957219-98AD82B5-1BF8-47B6-B923-862593EFC682Q40238903-64610455-2EB7-413D-8C6A-792F803FF289Q45404113-9C302DE1-B7FC-4388-A888-7BA29BDE4842Q46072220-5A22177B-ADB9-4DCA-9B63-B061BFA28E2DQ46833198-DE4997E3-CCBC-4475-91CE-9B0397C5CF8B
P2860
Risk of death associated with nesiritide in patients with acutely decompensated heart failure
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Risk of death associated with ...... ly decompensated heart failure
@ast
Risk of death associated with ...... ly decompensated heart failure
@en
Risk of death associated with ...... ly decompensated heart failure
@nl
type
label
Risk of death associated with ...... ly decompensated heart failure
@ast
Risk of death associated with ...... ly decompensated heart failure
@en
Risk of death associated with ...... ly decompensated heart failure
@nl
prefLabel
Risk of death associated with ...... ly decompensated heart failure
@ast
Risk of death associated with ...... ly decompensated heart failure
@en
Risk of death associated with ...... ly decompensated heart failure
@nl
P356
P1476
Risk of death associated with ...... ly decompensated heart failure
@en
P2093
Jonathan Sackner-Bernstein
Keith D Aaronson
P304
P356
10.1001/JAMA.296.12.1465
P407
P577
2006-09-27T00:00:00Z